AstraZeneca’s (AZN) Buy Rating Reaffirmed at Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZNFree Report) in a research note issued to investors on Thursday, Marketbeat reports.

AZN has been the subject of several other research reports. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a research report on Tuesday, November 28th. Barclays reaffirmed a buy rating and set a £135 ($169.24) price objective on shares of AstraZeneca in a research report on Monday, November 20th. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research report on Friday, November 17th. Jefferies Financial Group cut their price objective on shares of AstraZeneca from £130 ($162.97) to £125 ($156.70) and set a buy rating for the company in a research report on Monday, November 27th. Finally, Berenberg Bank reaffirmed a buy rating and set a £125 ($156.70) price objective on shares of AstraZeneca in a research report on Tuesday, November 21st. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, AstraZeneca currently has an average rating of Moderate Buy and a consensus price target of £118.95 ($149.12).

Read Our Latest Report on AstraZeneca

AstraZeneca Trading Up 1.2 %

Shares of AstraZeneca stock opened at GBX 9,940 ($124.61) on Thursday. The firm has a 50-day moving average of £104.80 and a 200-day moving average of £105.98. The stock has a market cap of £154.07 billion, a PE ratio of 3,307.41, a PEG ratio of 0.51 and a beta of 0.16. AstraZeneca has a 52-week low of GBX 9,700 ($121.60) and a 52-week high of £123.92 ($155.35). The company has a debt-to-equity ratio of 79.40, a quick ratio of 0.59 and a current ratio of 0.79.

AstraZeneca Increases Dividend

The company also recently announced a dividend, which will be paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd will be given a dividend of GBX 156 ($1.96) per share. This represents a yield of 1.49%. The ex-dividend date of this dividend is Thursday, February 22nd. This is an increase from AstraZeneca’s previous dividend of $71.80. AstraZeneca’s dividend payout ratio is currently 7,912.46%.

Insider Buying and Selling at AstraZeneca

In other news, insider Anna Manz bought 487 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was acquired at an average price of £101.90 ($127.74) per share, with a total value of £49,625.30 ($62,210.48). In related news, insider Michel Demare acquired 1,000 shares of the stock in a transaction dated Wednesday, November 22nd. The stock was bought at an average price of £101.70 ($127.49) per share, for a total transaction of £101,700 ($127,491.54). Also, insider Anna Manz acquired 487 shares of the stock in a transaction dated Tuesday, December 12th. The stock was bought at an average price of £101.90 ($127.74) per share, with a total value of £49,625.30 ($62,210.48). Insiders own 0.21% of the company’s stock.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.